The role of MXI1 in VHL deficient tumorigenesis

Cancer Biology and Therapy

Volumn 7, Issue 10, 2008, Pages 1628-1629

  Wong, Waihay J ^a,b   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

c MYC; HIF 1; HIF 2; MAX; MXI1; Renal cell carcinoma; VHL

Indexed keywords

BEVACIZUMAB; GLUCOSE TRANSPORTER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE; MXI1; ONCOPROTEIN; ORNITHINE DECARBOXYLASE; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SORAFENIB; SUNITINIB; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DIMERIZATION; GENE EXPRESSION REGULATION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KNOCKOUT GENE; NONHUMAN; NOTE; ONCOGENE C MYC; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSCRIPTION INITIATION; TUMOR GENE; UPREGULATION; VON HIPPEL LINDAU GENE;

EID: 54349097740     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.10.6917     Document Type: Note

References (17)

1. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1:439-44.
2. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. Jama 2006; 295:2516-24.
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81.
4. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. Embo J 2004; 23:1949-56.
5. Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, Huang LE. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005; 17:793-803.
6. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11:335-47.
7. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El-Deiry WS. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 2005; 4:1285-94.
8. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, Semenza GL. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11:407-20.
9. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 1995; 80:777-86.
10. Schreiber-Agus N, Meng Y, Hoang T, Hou H Jr, Chen K, Greenberg R, Cordon-Cardo C, Lee HW, DePinho RA. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998; 393:483-7.
11. Kuczyk MA, Serth J, Bokemeyer C, Schwede J, Herrmann R, Machtens S, Grunewald V, Hofner K, Jonas U. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer. Oncol Rep 1998; 5:213-6.
12. Ariyanayagam-Baksh SM, Baksh FK, Swalsky PA, Finkelstein SD. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma. Mod Pathol 2003; 16:992-5.
13. Boult JK, Taniere P, Hallissey MT, Campbell MJ, Tselepis C. Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network. Br J Cancer 2008; 98:1985-92.
14. Tsao CC, Teh BT, Jonasch E, Schreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 Suppresses HIF-2a-dependent Renal Cancer Tumorigenesis. Cancer Biol Ther 2008.
15. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1:237-46.
16. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25:5675-86.
17. Packham G, Cleveland JL. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol 1994; 14:5741-7.